Pulmonary infection in the immunocompromised patient.
Pneumonia in the immunocompromised patient remains a significant cause of morbidity and mortality. These patients are susceptible to a wide variety of organisms, but specific infections tend to occur in well defined settings. The type of infection can be predicted based on the nature and severity of the immune defect, past patient exposures, chemotherapy given, radiographic presentation, and acuteness of illness. New treatments, including growth factors, the oral antifungal agents, and antiviral drugs, such as ganciclovir and acyclovir, have improved management and prognosis in some cases. However, some problems have increased with a significant risk of spontaneous pneumothorax now seen with Pneumocystis carinii infection. Bronchoscopy with bronchoalveolar lavage plays a major role in diagnosis, particularly for P carinii and cytomegalovirus infection. However, open lung biopsy remains essential for diagnosis in some settings. Surgical resection for control of hemoptysis and for removal of residual foci of disease also are an integral part of management of pulmonary fungal infections in the immunosuppressed patient.
White
D A
DA
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
D017088:AIDS-Related Opportunistic Infections / Q000276:immunology*; D001706:Biopsy / Q000379:methods; D006801:Humans; D016867:Immunocompromised Host; D008168:Lung / Q000473:pathology; D008172:Lung Diseases, Fungal / Q000276:immunology*; D008174:Lung Diseases, Parasitic / Q000276:immunology*; D018410:Pneumonia, Bacterial / Q000276:immunology*; D011024:Pneumonia, Viral / Q000276:immunology*